BioCryst Pharmaceuticals (BCRX) Stock Rating Upgraded by BidaskClub

BioCryst Pharmaceuticals (NASDAQ:BCRX) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Thursday.

BCRX has been the topic of a number of other research reports. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Wednesday, November 8th. Royal Bank of Canada upgraded BioCryst Pharmaceuticals from a “sector perform” rating to an “outperform” rating and set a $6.00 target price on the stock in a research report on Tuesday, January 2nd. Finally, Barclays began coverage on BioCryst Pharmaceuticals in a research report on Wednesday, December 20th. They issued an “equal weight” rating and a $6.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $8.63.

Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) traded up $0.14 during mid-day trading on Thursday, hitting $4.94. The stock had a trading volume of 1,924,691 shares, compared to its average volume of 1,474,926. BioCryst Pharmaceuticals has a 1-year low of $3.95 and a 1-year high of $9.25. The stock has a market capitalization of $486.26, a price-to-earnings ratio of -7.72 and a beta of 2.81. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.53 and a quick ratio of 2.53.

In related news, CMO William P. Sheridan sold 64,310 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $4.72, for a total value of $303,543.20. The sale was disclosed in a document filed with the SEC, which is available at this link. 5.80% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of BCRX. Bank of New York Mellon Corp boosted its position in BioCryst Pharmaceuticals by 2.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 369,561 shares of the biotechnology company’s stock worth $2,055,000 after purchasing an additional 8,272 shares in the last quarter. Legal & General Group Plc boosted its position in BioCryst Pharmaceuticals by 4.9% in the 2nd quarter. Legal & General Group Plc now owns 18,346 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 860 shares in the last quarter. Teachers Advisors LLC boosted its position in BioCryst Pharmaceuticals by 55.9% in the 2nd quarter. Teachers Advisors LLC now owns 196,385 shares of the biotechnology company’s stock worth $1,092,000 after purchasing an additional 70,438 shares in the last quarter. TIAA CREF Investment Management LLC boosted its position in BioCryst Pharmaceuticals by 33.2% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 468,882 shares of the biotechnology company’s stock worth $2,607,000 after purchasing an additional 116,782 shares in the last quarter. Finally, Nationwide Fund Advisors boosted its position in BioCryst Pharmaceuticals by 4.5% in the 2nd quarter. Nationwide Fund Advisors now owns 46,149 shares of the biotechnology company’s stock worth $257,000 after purchasing an additional 1,975 shares in the last quarter. Hedge funds and other institutional investors own 84.79% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was published by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/02/11/biocryst-pharmaceuticals-bcrx-stock-rating-upgraded-by-bidaskclub.html.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply